Total Payments
$13,103
2024 Payments
$1,775
Companies
40
Transactions
621
Medicare Patients
4,288
Medicare Billing
$418,813
Payment Breakdown by Category
Food & Beverage$11,542 (88.1%)
Travel$1,547 (11.8%)
Education$13.89 (0.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $11,542 | 613 | 88.1% |
| Travel and Lodging | $1,547 | 7 | 11.8% |
| Education | $13.89 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Abbott Laboratories | $3,174 | 53 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $1,476 | 120 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $989.71 | 51 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $887.18 | 42 | $0 (2024) |
| Amgen Inc. | $813.50 | 39 | $0 (2024) |
| PFIZER INC. | $808.11 | 68 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $609.26 | 31 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $596.55 | 33 | $0 (2024) |
| Amarin Pharma Inc. | $520.61 | 29 | $0 (2023) |
| Impulse Dynamics (USA) Inc. | $337.29 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,775 | 65 | Abbott Laboratories ($491.11) |
| 2023 | $1,674 | 57 | Impulse Dynamics (USA) Inc. ($322.80) |
| 2022 | $1,210 | 64 | AstraZeneca Pharmaceuticals LP ($255.40) |
| 2021 | $1,529 | 105 | Janssen Pharmaceuticals, Inc ($320.50) |
| 2020 | $1,118 | 66 | Janssen Pharmaceuticals, Inc ($229.53) |
| 2019 | $1,343 | 88 | Janssen Pharmaceuticals, Inc ($276.76) |
| 2018 | $1,275 | 85 | PFIZER INC. ($165.55) |
| 2017 | $3,179 | 91 | Abbott Laboratories ($2,179) |
All Payment Transactions
621 individual payment records from CMS Open Payments — Page 1 of 25
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $14.49 | General |
| Category: Obesity | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $33.53 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/03/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $15.18 | General |
| Category: Cardiology | ||||||
| 10/28/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $17.43 | General |
| Category: Cardiology | ||||||
| 10/18/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $10.89 | General |
| Category: Cardiovascular | ||||||
| 10/16/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $9.98 | General |
| Category: Cardiovascular | ||||||
| 10/08/2024 | ABIOMED | Impella (Device) | Food and Beverage | Cash or cash equivalent | $33.67 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/24/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $14.19 | General |
| Category: Cardiovascular | ||||||
| 09/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $27.66 | General |
| Category: DIABETES | ||||||
| 09/18/2024 | Abbott Laboratories | JOT DX (Device) | Food and Beverage | In-kind items and services | $22.34 | General |
| Category: Cardiac Rhythm Management | ||||||
| 09/17/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $36.21 | General |
| Category: Not Applicable | ||||||
| 09/10/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $22.28 | General |
| Category: Cardiology | ||||||
| 09/05/2024 | Abbott Laboratories | JOT DX (Device) | Food and Beverage | In-kind items and services | $20.31 | General |
| Category: Cardiac Rhythm Management | ||||||
| 08/29/2024 | Abbott Laboratories | JOT DX (Device) | Food and Beverage | In-kind items and services | $147.62 | General |
| Category: Cardiac Rhythm Management | ||||||
| 08/23/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $30.52 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/21/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $11.94 | General |
| Category: Cardiovascular | ||||||
| 08/21/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $1.85 | General |
| Category: Cardiovascular | ||||||
| 08/16/2024 | Abbott Laboratories | CARDIOMEMS (Device) | Food and Beverage | In-kind items and services | $149.58 | General |
| Category: Heart Failure | ||||||
| 08/09/2024 | Abbott Laboratories | JOT DX (Device) | Food and Beverage | In-kind items and services | $21.59 | General |
| Category: Cardiac Rhythm Management | ||||||
| 08/08/2024 | Medtronic, Inc. | LINQ II (Device) | Food and Beverage | In-kind items and services | $35.81 | General |
| Category: Cardiac Diagnostics and Monitoring | ||||||
| 08/08/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $25.65 | General |
| Category: Not Applicable | ||||||
| 08/06/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $18.10 | General |
| Category: Cardiology | ||||||
| 08/05/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $29.36 | General |
| Category: DIABETES | ||||||
| 07/24/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $9.61 | General |
| Category: Cardiovascular | ||||||
| 07/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $33.92 | General |
| Category: DIABETES | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 987 | 1,890 | $367,745 | $89,801 |
| 2022 | 23 | 949 | 1,527 | $322,095 | $85,633 |
| 2021 | 21 | 1,050 | 1,470 | $404,757 | $114,605 |
| 2020 | 27 | 1,302 | 1,788 | $470,030 | $128,774 |
Total Patients
4,288
Total Services
6,675
Medicare Billing
$418,813
Procedure Codes
93
All Medicare Procedures & Services
93 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 159 | 229 | $70,150 | $21,264 | 30.3% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 32 | 32 | $66,930 | $11,829 | 17.7% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2023 | 43 | 193 | $31,010 | $11,320 | 36.5% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 31 | 124 | $11,780 | $5,327 | 45.2% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 83 | 203 | $21,560 | $4,598 | 21.3% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 59 | 68 | $19,120 | $3,805 | 19.9% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2023 | 83 | 200 | $24,765 | $3,493 | 14.1% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 203 | 311 | $22,175 | $3,473 | 15.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 19 | 23 | $9,825 | $3,299 | 33.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 41 | 48 | $10,375 | $3,007 | 29.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 29 | 29 | $9,105 | $2,958 | 32.5% |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 2023 | 32 | 64 | $3,840 | $2,822 | 73.5% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 17 | 17 | $16,680 | $2,791 | 16.7% |
| 93297 | Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | Office | 2023 | 26 | 127 | $11,595 | $2,570 | 22.2% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 43 | 43 | $14,870 | $2,218 | 14.9% |
| 93295 | Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | Office | 2023 | 24 | 65 | $11,535 | $1,913 | 16.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 11 | 11 | $4,365 | $1,363 | 31.2% |
| 93298 | Evaluation of cardiac rhythm monitor system, remote up to 30 days | Office | 2023 | 16 | 64 | $5,900 | $1,334 | 22.6% |
| 93228 | Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | Office | 2023 | 11 | 11 | $1,010 | $231.00 | 22.9% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 25 | 28 | $1,155 | $187.32 | 16.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 155 | 215 | $66,110 | $20,189 | 30.5% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2022 | 23 | 23 | $41,930 | $9,072 | 21.6% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2022 | 32 | 95 | $8,550 | $6,641 | 77.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 37 | 44 | $18,360 | $6,003 | 32.7% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 28 | 28 | $22,180 | $4,449 | 20.1% |
About Dr. Tracy Patel, M.D
Dr. Tracy Patel, M.D is a Cardiovascular Disease healthcare provider based in Bloomfield, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/14/2009. The National Provider Identifier (NPI) number assigned to this provider is 1013144369.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Tracy Patel, M.D has received a total of $13,103 in payments from pharmaceutical and medical device companies, with $1,775 received in 2024. These payments were reported across 621 transactions from 40 companies. The most common payment nature is "Food and Beverage" ($11,542).
As a Medicare-enrolled provider, Patel has provided services to 4,288 Medicare beneficiaries, totaling 6,675 services with total Medicare billing of $418,813. Data is available for 4 years (2020–2023), covering 93 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Bloomfield, CT
- Active Since 06/14/2009
- Last Updated 10/20/2016
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1013144369
Products in Payments
- EP Transseptal Access (Device) $1,796
- XARELTO (Drug) $1,449
- JARDIANCE (Drug) $824.44
- ELIQUIS (Drug) $542.34
- Vascepa (Drug) $520.61
- FARXIGA (Drug) $440.89
- Repatha (Biological) $416.53
- Corlanor (Drug) $396.97
- JOT DX (Device) $390.44
- BRILINTA (Drug) $377.01
- CARDIOMEMS (Device) $365.73
- CHANTIX (Drug) $361.15
- ENTRESTO (Drug) $358.76
- OPTIMIZER (Device) $322.80
- CAMZYOS (Drug) $318.78
- LEQVIO (Drug) $250.50
- EnSite Velocity System Expansion Modules (Device) $214.96
- Veltassa (Drug) $211.44
- PRADAXA (Drug) $204.06
- NEXLETOL (Drug) $202.98
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Bloomfield
Brett Nowlan, Md, MD
Cardiovascular Disease — Payments: $951,843
Cardiovascular Disease $951,843
Ronald Bloom, M.d, M.D
Cardiovascular Disease — Payments: $30,875
Cardiovascular Disease $30,875
Dr. Alan Lapa, M.d, M.D
Cardiovascular Disease — Payments: $28,329
Cardiovascular Disease $28,329
Vincent Romano, M.d, M.D
Cardiovascular Disease — Payments: $11,581
Cardiovascular Disease $11,581
Dr. Catalino Delacruz, M.d, M.D
Cardiovascular Disease — Payments: $10,399
Cardiovascular Disease $10,399
Maria Santos, M.d, M.D
Cardiovascular Disease — Payments: $10,382
Cardiovascular Disease $10,382